Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018
Prepared for publication in American Friends of the Hebrew University (AFHU), May 2018 Newsletter, Hebrew University’s HUJI Alumni Spotlight Section.
The profile was up on 5/3/2018 on AFHU website under the Alumni Spotlight at https://www.afhu.org/
Excerpts were Published in AFHU e-news on 5/11/2018.
https://us10.campaign-archive.com/?u=5c25136c60d4dfc4d3bb36eee&id=757c5c3aae&e=d09d2b8d72
https://www.afhu.org/2018/05/03/aviva-lev-ari/
Aviva Lev-Ari, PhD, RN – February 2018
- On 3/31/2018 was nominated for 2018 Yidan Foundation Prize.
About the Yidan Prize
Founded in 2016 by Dr Charles CHEN Yidan, the Yidan Prize has a mission to create a better world through education. Through a series of initiatives – research, events and multimedia content – alongside the annual award, the prize serves to establish a platform that allows the global community to engage in conversation around education and to play a role in education philanthropy.
On 9/27/2018 The Yidan Prize Announces Laureates 2018:
The Yidan Prize’s laureates this year are Northwestern University’s Professor Larry HEDGES and eDX’s founder and CEO, Professor Anant AGARWAL.
Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018
Please read about my Five Passions
- Cherry Blossom
When the cherry blossoms bloomed They brought beauty to my heart. Tatsu-jo¹
- Harp Music
The Role of the Harp and of Music in Medical Recovery
- Music and Curation in Music
Power of Analogy: Curation in Music, Music Critique as a Curation and Curation of Medical Research Findings – A Comparison
- Bob Dylan “for having created new poetic expressions within the great American song tradition”.
- 3D Printing in Fashion Design
3D Printing in Fashion Design – 2016 Exhibit at Museum of Fine Arts, Boston, #techstyle March 6, 2016 – July 10, 2016 Henry and Lois Foster Gallery (Gallery 158)
Autobiographical expressions made in the following creative writings:
- Autobiographical Annotations: Tribute to My Professors
- Public Eulogy of Note: Prof. Allan Pred, University of California, Berkeley
- Public Eulogy of Note: Prof. David Hooson, University of California, Berkeley
Education
- Elementary School Giv’at Nesher, Israel 1959-1964 (Top 5)
Recipient of National Award in Geography of Israel, 1963
- Huggim High School, Mount Carmel, Haifa, Israel, 1965-1968 (Top 5): Economics and Social Sciences concentration
- HUJI, BA, 1973 (with Distinction) Geography and History;
- HUJI, MA, 1976 (Summa Cum Laude) Urban Planning.
- University of California, Berkeley, PhD, 1983. Economic Geography and Industrial Organization Economics, Department of Geography.
- Northeastern University, Biological Sciences, 2005, Nursing, 2007.
My career had several phases:
- Phase 1: Research, 1973 – 1983
- Phase 2: Corporate Applied Research in the US, 1985 – 2005
- Phase 3: Career Reinvention in Health Care, 2005 – 2012
- Phase 4: Electronic Scientific Publishing, 4/2012 to Present
Phase 1: Research, 1973 – 1983
In Israel, Research Track
- Masters level in the Urban Studies Department, HUJI, 1973-1976; thesis advisor: Prof. Amiram Gonen
- Work and Welfare Research Institute (WWRI), HUJI, 1975-1976, research assistant to Prof. Shalom Reichman, WWRI director: Prof. Rivka W. Bar-Yosef, and
- Technion, Transportation Research Center (TRC), 1977-1978, research associate and team leader, in Dr. Moshe Becker’s group, Road Safety Center (RSC).
My education at HUJI was crucial in attaining a Research Associate position at the Technion, 1977-1978. The years of research for my Masters at HUJI and the two years at the Technion contributed to my professional motivation and confidence to pursue a PhD at University of California, Berkeley, 9/1978 – 12/1983.
I arrived at my first research position at the Technion following my Masters at HUJI. I was extremely well prepared for the challenge. I was well versed in research methodologies and mastered advanced skills in scientific and technical oral and written communication. These most important skills served me very well three years later when I started my doctorate at University of California, Berkeley.
My professors at HUJI wrote recommendation letters for me which where critical for admission to the PhD program. I remained in contact with them till some passed away, Prof. Louis Guttman in 1989 and Prof. Shalom Reichman in 1994. I am in contact to this day with Prof. Ruth Kark, Dr. Shlomit Levy, and Dr. Sara Hershkovits. I was one of their very able students. On my annual visit in Israel, I meet with all the three.
In California, Doctoral Program at Berkeley, Industrial Organization Economics, Economic Geography, 9/1978 – 12/1983. Advisor: Prof. Allan Pred
Comments I made on 3/8/2018 to Nathan F. SAYRE, department chairman:
“The death of Allan Pred, was a colossal loss to humanity and to human geography. Like Albert Einstein’s death was an irrecoverable loss to the physics community and to the universe he researched and modeled!!!”
My own dissertation was creative and led to my first job in the US, after graduation, director level at SRI, International in Menlo Park, CA
Without the aura of a Berkeley PhD – I could not have been able to carry the torch that guided me to where I am in 2018, an owner of a knowledge-based venture with significant intellectual property, planning to transfer ownership in 2019/20.
I have expressed my feelings and impressions of my years at Berkeley in the following two articles:
- Recollections: Part 1 – My days at Berkeley, 9/1978 – 12/1983 –About my doctoral advisor, Allan Pred, other Professors and other Peers
- Recollections: Part 2 – “While Rolling” is preceded by “While Enrolling” Autobiographical Alumna Recollections of Berkeley – Aviva Lev-Ari, PhD’83
Phase 2: Corporate Applied Research in the US, 1985 – 2005
Twenty years of top-tier management consulting and as a corporate executive. In the corporate world, I worked for Fortune 50 companies, using the principles of statistical modeling, economic geography, and of industrial organization economics, every day.
See
Accomplishments
- Technology Executive, Methodology and Decision Scientist, Functional CV
- Contributions to Design of Algorithm-based Decision Support Systems
- Technical Contributions in the Domain of Electronic Commerce Analytics: Aviva Lev-Ari, Ph.D.
Data Science is the Greatest Science. It is the Greatest Science for Women, as Well
Phase 3: Career Reinvention in Health Care, 2005 – 2012
Education
- Northeastern University, Biological Sciences, 2005
- Northeastern University, Nursing, 2007, National Nursing Board, 1/2008
Work experience in Health Care
https://pharmaceuticalintelligence.com/founder/scientific-and-medical-affairs-chronological-cv/
- Delivery of Care in MA – Post Acute Nursing Management positions, 2008 – 2012
HealthCare Delivery – Long Term Post Acute Care Nursing Management CV
- Cardiovascular pharmacology-therapy research, development of a combination drug therapy, 2006-2007, Northeastern University, with Prof. Paul Aburjaily, PharmD
- Conceptual development with a team of scientists on Drug Discovery & Drug Delivery, 2015-2016, LPBI Group, with Dr. Raphael Nir, SBH Sciences, CEO.
https://pharmaceuticalintelligence.com/drugdiscovery-lpbi-group/
Phase 4: Electronic Scientific Publishing, 4/2012 to Present
- 2012 – Present, Editor-in-Chief, Open Access Online Scientific Journal
https://pharmaceuticalintelligence.com/about/
Site statistics on 5/26/2018:
- 1,435,270 e-Readers,
- 2,340 subscribers,
- 5,318 Scientific Articles,
- ~8000 comments by scientists
- Editor-in-Chief of 13 Volumes of a 16-Volume LPBI’s BioMed e-Series, published, 2013 – 2017, available on Amazon.com shelves in Medicine and Life Sciences. Three additional volumes will be published in 2018/9:
Aviva’s Page on Amazon.com
- 557 Co-Curations, single author curations and scientific reports in 13 Volumes of LPBI’s BioMed e-Series by Aviva Lev-Ari, PhD, RN
https://www.linkedin.com/pulse/557-co-curations-single-author-curation-scientific-13-aviva/
- Press coverage of BioMed and BioTech Conferences in Real Time, attendance on Press Pass
https://pharmaceuticalintelligence.com/press-coverage/
Additional Sources for Chronological CV
https://pharmaceuticalintelligence.com/founder/
- Scientific and Medical Affairs Chronological CV
- Technology Executive, Methodology and Decision Scientist, Functional CV
- Contributions to Design of Algorithm-based Decision Support Systems
- Technical Contributions in the Domain of Electronic Commerce Analytics: Aviva Lev-Ari, Ph.D.
- HealthCare Delivery – Long Term Post Acute Care Nursing Management CV
- Editorial & Publication of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence
- List of Invited Lectures, 1983 -2004
- List of Publications, 1983 – 2004
- List of Publications, 2006 – Present
- Cardiovascular Diseases and Pharmacological Therapy: Curations
- MedTech & Medical Devices for Cardiovascular Repair – Curations
- Stem Cells and Cardiac Repair: Content Curation & Scientific Reporting
- Regulatory Affairs: Publications on FDA-related Issues – Aviva Lev-Ari, PhD, RN
- Cancer Research: Curations and Reporting
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
Rosalind Codrington, PhD
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
vaishnavee24
zraviv06
zs22
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.